Dr. Neill Raoul Graff-Radford, MD

Dr. Graff-Radford practices at Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic.

Dr. Graff-Radford's NPI, 1851380208, was assigned on October 18, 2005. Dr. Graff-Radford graduated from University of the Witwatersrand in 1973. Dr. Graff-Radford holds Florida license ME56097.

Dr. Graff-Radford's primary practice is Mayo Clinic Hospital, at 4500 San Pablo Rd, Jacksonville, FL 32224 in Duval County. The practice phone is (904) 953-2000.

Dr. Graff-Radford's primary practice is Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic. The medical group on file is Mayo Clinic Jacksonville.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Graff-Radford practices. Vendor and product names are available with a free account.

Neurology is Dr. Graff-Radford's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Graff-Radford is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Graff-Radford's licenses on file in 3 states: Florida, Iowa and Colorado.

Dmand AI lists alzheimer's disease, encephalopathy, muscle weakness, neck pain and spine problems, non-alzheimer's dementia (chronic) and vertigo among the conditions Dr. Graff-Radford treats.

CMS data shows 295 Medicare services from Dr. Graff-Radford across 5 procedure codes in 2024, for 223 Medicare patients. Medicare paid $28,506 for them. Every service was in an office.

CMS counts 223 Medicare patients who saw Dr. Graff-Radford in 2024. The largest group is 75 to 84, with 118 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.26, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Graff-Radford's median patient age at 69, with 44% women.

In 2024, Dr. Graff-Radford wrote 68 Medicare Part D claims for 19 patients. 100% of them were for generic drugs. CMS names the drug for 53 of them, across 1 drug with 11 or more claims each, at $709 in total drug cost. In 2023, CMS named 54 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Graff-Radford for performance year 2024, reported as part of a group. Dr. Graff-Radford accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Graff-Radford as offering telehealth.

Dmand AI links 382 papers to Dr. Graff-Radford, published from 2006 to 2025. 2023 was the busiest year, with 24. The most frequent topics are Alzheimer Disease, Brain and Neuropsychological Tests. Dr. Graff-Radford has published most often in Neurology. Dr. Graff-Radford's most frequent co-authors are Dennis Dickson, MD, Bradley F. Boeve, MD and Zbigniew Wszolek, MD.

Dmand AI links Dr. Graff-Radford to 12 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Cognition Disorders, Cognitive Dysfunction and Alzheimer Disease. Mayo Clinic sponsors the most, 5. Open Payments lists research payments to Dr. Graff-Radford that name 4 trials.

CMS Open Payments shows 9 general payments to Dr. Graff-Radford from 1 drug or device company from 2016 to 2017. Travel and lodging make up the largest share, 66% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,740. It also lists 6 research payments totaling $2,652 from 2016 to 2022, naming 4 clinical trials.

Dr. Graff-Radford graduated from University of the Witwatersrand in 1973.

Dr. Graff-Radford is in network with 8 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.